Niagen Bioscience (NASDAQ:NAGE – Get Free Report) and Coty (NYSE:COTY – Get Free Report) are both consumer staples companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability and institutional ownership.
Earnings & Valuation
This table compares Niagen Bioscience and Coty”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Niagen Bioscience | $129.42 million | 1.23 | $17.38 million | $0.12 | 16.75 |
| Coty | $5.78 billion | 0.63 | -$604.80 million | ($0.65) | -6.41 |
Niagen Bioscience has higher earnings, but lower revenue than Coty. Coty is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Niagen Bioscience and Coty’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Niagen Bioscience | 8.37% | 10.18% | 7.57% |
| Coty | -9.74% | 7.11% | 2.28% |
Volatility & Risk
Niagen Bioscience has a beta of 2.12, meaning that its stock price is 112% more volatile than the S&P 500. Comparatively, Coty has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.
Institutional and Insider Ownership
15.4% of Niagen Bioscience shares are owned by institutional investors. Comparatively, 42.4% of Coty shares are owned by institutional investors. 10.0% of Niagen Bioscience shares are owned by company insiders. Comparatively, 0.4% of Coty shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of recent ratings and target prices for Niagen Bioscience and Coty, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Niagen Bioscience | 0 | 1 | 4 | 1 | 3.00 |
| Coty | 2 | 10 | 1 | 0 | 1.92 |
Niagen Bioscience currently has a consensus target price of $8.50, indicating a potential upside of 322.89%. Coty has a consensus target price of $3.48, indicating a potential downside of 16.40%. Given Niagen Bioscience’s stronger consensus rating and higher possible upside, research analysts plainly believe Niagen Bioscience is more favorable than Coty.
Summary
Niagen Bioscience beats Coty on 13 of the 15 factors compared between the two stocks.
About Niagen Bioscience
Niagen Bioscience, Inc. develops and markets products based on nicotinamide riboside (NR), a form of vitamin B3 studied for its role in supporting the body’s production of NAD+. Its offerings include Tru Niagen, a consumer dietary supplement, and Niagen, a branded NR ingredient supplied to other businesses. The company also conducts and supports research on NR, NAD+ and healthy aging. It was formerly known as ChromaDex Corporation and adopted the Niagen Bioscience name in 2025. Niagen Bioscience serves consumers and commercial customers in the United States and international markets through online sales, retail and distribution channels.
About Coty
Coty is a global beauty company that develops, manufactures, markets and distributes fragrances, cosmetics, skin care and body-care products. Its portfolio spans prestige and consumer beauty, with products sold in markets around the world. The company’s brands include CoverGirl, Rimmel London, Max Factor and Sally Hansen. Coty also produces fragrances and beauty products under license for a range of fashion and lifestyle brands. Founded in Paris in 1904 by perfumer François Coty, the company has grown from a fragrance business into a broad-based beauty group.
Receive News & Ratings for Niagen Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Niagen Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
